4SC develops small molecule drugs for the treatment of cancer in indications with a high unmet medical need. In doing so, we strive to offer patients treatment options that are more effective and better tolerated as well as a better quality of life.
The 4SC product pipeline currently comprises one drug candidate in clinical development, resminostat.
Resminostat is an orally administered histone deacetylase (HDAC) inhibitor with an innovative mechanism of action that potentially represents a novel therapy for a broad spectrum of oncology indications, both in monotherapy and particularly in combination with other anti-cancer drugs.
Assets available for out-licensing
4SC is focused on developing small molecule drugs for the treatment of cancer. All other assets are available for partnering or out-licensing.
4SC has out-licensed and partnered drug candidates to several national and international pharma and biotech companies.